Liquidia (LQDA) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Liquidia in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LQDA shares.
View LQDA analyst ratings or view top-rated stocks.

4 brokerages have issued twelve-month price targets for Liquidia's shares. Their LQDA share price forecasts range from $3.00 to $20.00. On average, they predict the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 57.5% from the stock's current price.
View analysts price targets for LQDA or view top-rated stocks among Wall Street analysts.

Liquidia's stock was trading at $6.37 at the beginning of 2023. Since then, LQDA stock has increased by 39.6% and is now trading at $8.89.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our LQDA earnings forecast.

Liquidia Co. (NASDAQ:LQDA) released its earnings results on Thursday, March, 16th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The firm earned $5.36 million during the quarter, compared to the consensus estimate of $3.65 million. Liquidia had a negative net margin of 217.39% and a negative trailing twelve-month return on equity of 39.89%.

ETFs with the largest weight of Liquidia (NASDAQ:LQDA) stock in their portfolio include SPDR S&P Kensho New Economies Composite ETF (KOMP), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC),

Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA).

(LQDA) raised $50 million in an initial public offering (IPO) on Thursday, July 26th 2018. The company issued 4,500,000 shares at a price of $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Liquidia trades on the NASDAQ under the ticker symbol "LQDA."

Liquidia's stock is owned by many different institutional and retail investors. Top institutional shareholders include Caligan Partners LP (14.28%), BlackRock Inc. (5.00%), State Street Corp (4.11%), Geode Capital Management LLC (1.44%), Two Sigma Advisers LP (0.89%) and Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.86%). Insiders that own company stock include Arthur S Kirsch, Caligan Partners Lp, Eshelman Ventures, Llc, Michael Kaseta, Paul B Manning, Robert A Lippe, Roger Jeffs, Russell Schundler and Scott Moomaw.
View institutional ownership trends.

Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LQDA stock can currently be purchased for approximately $8.89.

Liquidia (NASDAQ:LQDA) has a market capitalization of $575.36 million and generates $15.94 million in revenue each year. The company earns $-41,010,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

Liquidia's mailing address is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. The official website for the company is www.liquidia.com. The company can be reached via phone at (919) 328-4400 or via email at ir@liquidia.com.